Rejection: T Cell-Mediated and Antibody-Mediated
View More View Less
  • 1 Division of Nephrology and Transplantation, Maine Medical Center, and Tufts University School of Medicine, Portland, Maine
  • 2 Division of Renal Diseases and Hypertension, Transplant Center, University of Colorado Denver, Aurora, Colorado
  • 1.

    Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, : The Banff 2017 kidney meeting report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant 18: 293307, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Loupy A, Haas M, Solez K, Racusen L, Glotz D, Seron D, : The Banff 2015 kidney meeting report: Current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant 17: 2841, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Halloran PF, Famulski KS, Chang J: A Probabilistic approach to histologic diagnosis of antibody-mediated rejection in kidney transplant biopsies. Am J Transplant 17: 129139, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Halloran PF, Matas A, Kasiske BL, Madill-Thomsen KS, Mackova M, Famulski KS: Molecular phenotype of kidney transplant indication biopsies with inflammation in scarred areas. Am J Transplant 19: 13561370, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Haas M: The relationship between pathologic lesions of active and chronic antibody-mediated rejection in renal allografts. Am J Transplant 18: 28492856, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Roufosse C, Simmonds N, Clahsen-van Groningen M, Haas M, Henriksen KJ, Horsfield C, : A 2018 reference guide to the Banff classification of renal allograft pathology. Transplantation 102: 17951814, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Nankivell BJ, Shingde M, Keung KL, Fung CL, Borrows RJ, O’Connell PJ, : The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: The Banff i-IFTA lesion. Am J Transplant 18: 364376, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Lefaucheur C, Gosset C, Rabant M, Viglietti D, Verine J, Aubert O, : T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. Am J Transplant 18: 377390, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Mehta R, Bhusal S, Randhawa P, Sood P, Cherukuri A, Wu C, : Short-term adverse effects of early subclinical allograft inflammation in kidney transplant recipients with a rapid steroid withdrawal protocol. Am J Transplant 18: 17101717, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Seifert ME, Yanik MV, Feig DI, Hauptfeld-Dolejsek V, Mroczek-Musulman EC, Kelly DR, : Subclinical inflammation phenotypes and long-term outcomes after pediatric kidney transplantation. Am J Transplant 18: 21892199, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Torres IB, Reisaeter AV, Moreso F, Âsberg A, Vidal M, Garcia-Carro C, : Tacrolimus and mycophenolate regimen and subclinical tubulo-interstitial inflammation in low immunological risk renal transplants. Transpl Int 30: 11191131, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Senev A, Coemans M, Lerut E, Van Sandt V, Daniëls L, Kuypers D, : Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome. Am J Transplant 19: 763780, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Deltombe C, Gillaizeau F, Anglicheau D, Morelon E, Trébern-Launay K, Le Borgne F, : Is pre-transplant sensitization against angiotensin II type 1 receptor still a risk factor of graft and patient outcome in kidney transplantation in the anti-HLA luminex era? A retrospective study. Transpl Int 30: 11501160, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Pearl MH, Zhang Q, Palma Diaz MF, Grotts J, Rossetti M, Elashoff D, : Angiotensin II type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation. Kidney Int 93: 260269, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    See SB, Aubert O, Loupy A, Veras Y, Lebreton X, Gao B, : Post-transplant natural antibodies associate with kidney allograft injury and reduced long-term survival. J Am Soc Nephrol 29: 17611770, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Aubert O, Loupy A, Hidalgo L, Duong van Huyen JP, Higgins S, Viglietti D, : Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients. J Am Soc Nephrol 28: 19121923, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Haas M, Mirocha J, Reinsmoen NL, Vo AA, Choi J, Kahwaji JM, : Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies. Kidney Int 91: 729737, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Kamburova EG, Wisse BW, Joosten I, Allebes WA, van der Meer A, Hilbrands LB, : Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant. Am J Transplant 18: 22742284, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Wiebe C, Gareau AJ, Pochinco D, Gibson IW, Ho J, Birk PE, : Evaluation of C1q status and titer of de novo donor-specific antibodies as predictors of allograft survival. Am J Transplant 17: 703711, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Kamburova EG, Wisse BW, Joosten I, Allebes WA, van der Meer A, Hilbrands LB, : Pretransplant C3d-fixing donor-specific anti-HLA antibodies are not associated with increased risk for kidney graft failure. J Am Soc Nephrol 29: 22792285, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Courant M, Visentin J, Linares G, Dubois V, Lepreux S, Guidicelli G, : The disappointing contribution of anti-human leukocyte antigen donor-specific antibodies characteristics for predicting allograft loss. Nephrol Dial Transplant 33: 18531863, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22.

    Viglietti D, Loupy A, Vernerey D, Bentlejewski C, Gosset C, Aubert O, : Value of donor-specific anti-HLA antibody monitoring and characterization for risk stratification of kidney allograft loss. J Am Soc Nephrol 28: 702715, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Michielsen LA, Wisse BW, Kamburova EG, Verhaar MC, Joosten I, Allebes WA, : A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival. Nephrol Dial Transplant 34: 10561063, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24.

    Wehmeier C, Hönger G, Cun H, Amico P, Hirt-Minkowski P, Georgalis A, : Donor specificity but not broadness of sensitization is associated with antibody-mediated rejection and graft loss in renal allograft recipients. Am J Transplant 17: 20922102, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25.

    Gosset C, Viglietti D, Rabant M, Vérine J, Aubert O, Glotz D, : Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis. Kidney Int 92: 729742, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26.

    Leeaphorn N, Pena JRA, Thamcharoen N, Khankin EV, Pavlakis M, Cardarelli F: HLA-DQ mismatching and kidney transplant outcomes. Clin J Am Soc Nephrol 13: 763771, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27.

    Wiebe C, Kosmoliaptsis V, Pochinco D, Gibson IW, Ho J, Birk PE, : HLA-DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity. Am J Transplant 19: 17081719, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Lachmann N, Niemann M, Reinke P, Budde K, Schmidt D, Halleck F, : Donor-recipient matching based on predicted indirectly recognizable HLA epitopes independently predicts the incidence of de novo donor-specific HLA antibodies following renal transplantation. Am J Transplant 17: 30763086, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29.

    Davis S, Gralla J, Klem P, Tong S, Wedermyer G, Freed B, : Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant 18: 907915, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Wiebe C, Rush DN, Nevins TE, Birk PE, Blydt-Hansen T, Gibson IW, : Class Ii eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development. J Am Soc Nephrol 28: 33533362, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    Béland MA, Lapointe I, Noël R, Côté I, Wagner E, Riopel J, : Higher calcineurin inhibitor levels predict better kidney graft survival in patients with de novo donor-specific anti-HLA antibodies: A cohort study. Transpl Int 30: 502509, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32.

    Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, : Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 374: 333343, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33.

    Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L, : Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT. Am J Transplant 18: 17741782, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34.

    Schinstock CA, Cosio F, Cheungpasitporn W, Dadhania DM, Everly MJ, Samaniego-Picota MD, : The value of protocol biopsies to identify patients with de novo donor-specific antibody at high risk for allograft loss. Am J Transplant 17: 15741584, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35.

    Parajuli S, Reville PK, Ellis TM, Djamali A, Mandelbrot DA: Utility of protocol kidney biopsies for de novo donor-specific antibodies. Am J Transplant 17: 32103218, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36.

    Parajuli S, Redfield RR, Garg N, Aziz F, Mohamed M, Astor BC, : Clinical significance of microvascular inflammation in the absence of anti-HLA DSA in kidney transplantation. Transplantation 103: 14681476, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 37

    Ciancio G, Gaynor JJ, Guerra G, Sageshima J, Roth D, Chen L, : Antibody-mediated rejection implies a poor prognosis in kidney transplantation: Results from a single center. Clin Transplant 32: e13392, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 38.

    Wan SS, Ying TD, Wyburn K, Roberts DM, Wyld M, Chadban SJ: The treatment of antibody-mediated rejection in kidney transplantation: An updated systematic review and meta-analysis. Transplantation 102: 557568, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39.

    Viglietti D, Loupy A, Aubert O, Bestard O, Duong Van Huyen JP, Taupin JL, : Dynamic prognostic score to predict kidney allograft survival in patients with antibody-mediated rejection. J Am Soc Nephrol 29: 606619, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40.

    Lefaucheur C, Viglietti D, Hidalgo LG, Ratner LE, Bagnasco SM, Batal I, : Complement-activating anti-HLA antibodies in kidney transplantation: Allograft gene expression profiling and response to treatment. J Am Soc Nephrol 29: 620635, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 41.

    Viglietti D, Bouatou Y, Kheav VD, Aubert O, Suberbielle-Boissel C, Glotz D, : Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection. Kidney Int 94: 773787, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42.

    Bailly E, Anglicheau D, Blancho G, Gatault P, Vuiblet V, Chatelet V, : Prognostic value of the persistence of C1q-binding anti-HLA antibodies in acute antibody-mediated rejection in kidney transplantation. Transplantation 102: 688698, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 43.

    Moreso F, Crespo M, Ruiz JC, Torres A, Gutierrez-Dalmau A, Osuna A, : Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial. Am J Transplant 18: 927935, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 44.

    Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, : A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol 29: 591605, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 45.

    Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, : Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant 17: 23812389, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 46.

    Kulkarni S, Kirkiles-Smith NC, Deng YH, Formica RN, Moeckel G, Broecker V, : Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: A pilot randomized controlled trial. Am J Transplant 17: 682691, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 47.

    Eskandary F, Jilma B, Mühlbacher J, Wahrmann M, Regele H, Kozakowski N, : Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection: Results from a first-in-patient phase 1 trial. Am J Transplant 18: 916926, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 200 201 15
Full Text Views 518 518 40
PDF Downloads 329 329 20